Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan vs Chemotherapy in Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
NCT07419295Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Apr 2026
- Primary completion
- Jul 2029
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 17
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in urothelial carcinoma (UC), sponsored by Merck & Co.. Started Apr 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07419295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07419295.